All News

myositis.jpg

Uncertainty with immunosuppressive for idiopathic inflammatory myopathies

Jack Cush, MD

A current Cochrane review suggests a continued unmet need regarding the status and utility of targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies (IIM). Overall there has been little progress since the previous Cochrane review (2012) that found little or no evidence to guide treatment.

Read Article
RheumNow Podcast square

Teaching You How to Think… (8.15.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogren's trial, to PT or not to PT, and  aphorisms to live by.

Read Article
GCA.glossary.wordle

Glossary for Giant Cell Arteritis

Jack Cush, MD

 

Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.

Read Article
Patient,instruction

The Patient Journey with Rheumatic Disease

Jack Cush, MD

Oton and colleagues have reviewed the "patient journey" - from symptoms to specialty referral in those diagnosed with rheumatic and musculoskeletal diseases (RMDs).

Read Article
switch.jpg

Biologic Switching in Psoriasis

Jack Cush, MD

A systematic review and meta-analysis found that biologic switching was effective in a significant number of psoriasis patients; but there may be a price to pay. 

Read Article
liveVote2.jpg

Rheums Speak: Changing Rheumatology Practices & Choices

Jack Cush, MD

RheumNow surveyed clinicians worldwide on how their rheumatology practice, treatment decisions, and career outlooks have changed over the past 20 years. 242 respondents (68% from the USA) shared their perspectives on the changing landscape of rheumatoid arthritis care, practice patterns, and professional development.

Read Article
TNF Inhibitors in Takayasu's Arteritis A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis. https://t.co/lJbvaYnylO https://t.co/uRBruhW2Fd

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves 1st new Fibromyalgia drug in 15 yrs - Tonmya (cyclobenzaprine HCl sublingual) as treatment of fibromyalgia in adults. Based on 2 phase 3 trials and 1400+ pts. Dose 2.8 mg tabs 1-2 SL qhs (peak concentration 4.3 hours; t1/2 life = 36 hrs, longer w/ elderly, liver dz) https://t.co/8DVRet5sjU
Dr. John Cush RheumNow ( View Tweet)
Advances in Still's disease Rx: - using IL-1 or IL-6 inhibitors 1st line - New FDA approval of emapalumab (IFNg) for MAS - unclear if biologics can cause lung probs in Stills https://t.co/zSqTcOSVGE https://t.co/8GhoamkV4N

Links:

Dr. John Cush RheumNow ( View Tweet)
Inefficiencies of ANA Testing The Journal of Rheumatology has published an analysis of antinuclear antibody (ANA) multiplex testing showing its nonspecific utility and poor rate of return in identifying ANA-associated autoimmune rheumatic disease (ARDs). https://t.co/85B70egGBw
Dr. John Cush RheumNow ( View Tweet)
Wondering what rheumatoid arthritis experts think about the future of treatment? Dr. Jack Cush moderates a special Tuesday Nite Rheumatology session, live at 7 PM ET on August 26th, where experts will dive into a nationwide survey on the evolution of biologics and DMARDs. Hear https://t.co/afYRarqjvj
Dr. John Cush RheumNow ( View Tweet)
Biologic Switching in Psoriasis A systematic review and meta-analysis found that biologic switching was effective in a significant number of psoriasis patients; but there may be a price to pay. https://t.co/QEv5jx9AIo https://t.co/06keUfXwRT

Links:

Dr. John Cush RheumNow ( View Tweet)
2025 ACR Guidance on Diagnosis and Management of VEXAS The ACR has published a formal international consensus guidance on VEXAS as a resource for clinicians seeking to understand the disease and its management. https://t.co/KoNjOiKdTq https://t.co/9bIZgvP8kD

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective study 1,237 pregnant women (APS excluded) - finding LA-RVVT, anti-β2GPI IgG, predicted preeclampsia & intrauterine fetal death (IUFDR) and were were in identifying obstetric antiphospholipid syndrome (APS) https://t.co/5zKpR9NTcw https://t.co/6HXID7gtwR

Links:

Dr. John Cush RheumNow ( View Tweet)
Advances in Still's disease Rx: - using IL-1 or IL-6 inhibitors 1st line - New FDA approval of emapalumab (IFNg) for MAS - unclear if biologics can cause lung probs in Stills https://t.co/zSqTcOSVGE https://t.co/qefCt5b7qh

Links:

Dr. John Cush RheumNow ( View Tweet)
Repurposing & Pipeline (8.8.2025) Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this week’s podcast. https://t.co/Hx1aAdiTOy https://t.co/gwyDweXIbS

Links:

Dr. John Cush RheumNow ( View Tweet)
Inefficiencies of ANA Testing The Journal of Rheumatology has published an analysis of antinuclear antibody (ANA) multiplex testing showing its nonspecific utility and poor rate of return in identifying ANA-associated autoimmune rheumatic disease (ARDs). https://t.co/hojdPPtCcI
Dr. John Cush RheumNow ( View Tweet)
2025 BSR Recommendations for ANCA-associated Vasculitis The BSR and BHPR have published a guideline for the management of adults with AAV; specifically three conditions: GPA, MPA, and EGPA. https://t.co/nYpbBK7Ahr https://t.co/XcfL4KRHlj

Links:

Dr. John Cush RheumNow ( View Tweet)
Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTUNUS-1 and NEPTUNUS-2, met met primary endpoints w/ statistically significant improvements in disease activity in Sjögren’s patients. https://t.co/cIBhF3YJh3 https://t.co/YRTq6LEFhm

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves Vagal Nerve Stimulator for RA SetPoint Medical announced the FDA approved the SetPoint System, a neuroimmune modulation treatment for moderate-to-severe rheumatoid arthritis (RA), for patients not well-managed or cannot tolerate—existing RA therapies like https://t.co/MtVny1iBQ4
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×